EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Preventive Effects of a CVD Polypill on Developing Diabetes Among Patients With Metabolic Syndrome: Results of the PolyIran-Liver Trial

Elham Jafari iD, Hossein Poustchi iD, Abbas Mohagheghi, Maryam Sharafkhah, Masoud Khoshnia iD, Alireza Nateghi, Shahin Merat iD, Reza Malekzadeh iD

Archives of Iranian Medicine · 2024

DOI: 10.34172/aim.31839 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Archives of Iranian Medicine, 2024. Verfasst von Elham Jafari und 7 weiteren Autor:innen. Beteiligte Einrichtung: Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Metabolic Syndrome, Atorvastatin, Blood Glucose, Cardiovascular Diseases. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While cardiovascular disease (CVD) polypills have demonstrated significant benefits in preventing CVD events by managing CVD risk factors and improving patient adherence, their effects on blood glucose levels, an important risk factor for CVD, remain unknown.

Methods

We analyzed data from the PolyIran-Liver trial, which involved 1,508 participants aged 50 and above. Of these, 787 were randomly assigned to receive a polypill (consisting of aspirin, atorvastatin, hydrochlorothiazide, and valsartan), while 721 received usual care as the control group over a five-year period. The aim was to determine whether there were any significant differences in fasting blood sugar (FBS) levels between the two groups at baseline, middle, and end of the study. The data analysis focused on three subgroups: participants with diabetes, those with metabolic syndrome (MetS) but without diabetes, and participants without diabetes or MetS.

Results

Of the total studied population, with a mean age of 59±6.7 years, 328(22%) were identified with diabetes, 371 (25%) with MetS but without diabetes, and 809 (54%) without diabetes or MetS. We observed a trend of rising FBS levels until month 30, followed by a subsequent decline at month 60. Participants in the polypill group exhibited lower FBS levels than the control group at both time points, with statistically significant differences in all three subgroups at month 30 and in the MetS-without diabetes at month 60 (mean difference: -9.3 mg/dl, 95% CI: 13.9 to -4.6).

Conclusion

The polypill used in this study may have the potential to delay the onset of diabetes in patients with MetS more effectively than in the general population. However, its beneficial effects on the blood sugar levels of diabetic individuals require further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromeAtorvastatinBlood GlucoseCardiovascular DiseasesAspirinHydrochlorothiazideValsartanHumansMiddle AgedMaleFemaleAgedDrug CombinationsDiabetes MellitusIranAntihypertensive Agents

Stichwörter der Autor:innen

Cardiovascular diseaseDiabetes mellitesFixed dose combinationMetabolic syndromePolypillPrimary prevention

Substanzen

AtorvastatinBlood GlucoseAspirinHydrochlorothiazideValsartanDrug CombinationsAntihypertensive Agents

Autor:innen und Institutionen

  • Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Cardiology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.
  • Research and Development Department, Alborz-Darou Pharmaceutical Co., Ghazvin, Iran.

ORCID-Profile: Elham Jafari, Hossein Poustchi, Masoud Khoshnia, Shahin Merat, Reza Malekzadeh

Zitieren

APA

Jafari, E., Poustchi, H., Mohagheghi, A., Sharafkhah, M., Khoshnia, M., Nateghi, A., Merat, S., & Malekzadeh, R. (2024). Preventive Effects of a CVD Polypill on Developing Diabetes Among Patients With Metabolic Syndrome: Results of the PolyIran-Liver Trial. Archives of Iranian Medicine. https://doi.org/10.34172/aim.31839

Vancouver

Jafari E, Poustchi H, Mohagheghi A, Sharafkhah M, Khoshnia M, Nateghi A, et al. Preventive Effects of a CVD Polypill on Developing Diabetes Among Patients With Metabolic Syndrome: Results of the PolyIran-Liver Trial. Archives of Iranian Medicine. 2024. doi:10.34172/aim.31839

BibTeX
@article{Jafari2024,
  author = {Jafari, Elham and Poustchi, Hossein and Mohagheghi, Abbas and Sharafkhah, Maryam and Khoshnia, Masoud and Nateghi, Alireza and Merat, Shahin and Malekzadeh, Reza},
  title = {Preventive Effects of a CVD Polypill on Developing Diabetes Among Patients With Metabolic Syndrome: Results of the PolyIran-Liver Trial},
  journal = {Archives of Iranian Medicine},
  year = {2024},
  doi = {10.34172/aim.31839}
}
Kostenlos starten →